Findings

What do systematic reviews say?

3,703 questions · 3,824 findings · 858 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 573 · 15%GRADE not reported 383 · 10%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Transdermal beta‐estradiol patch vs conjugated equine estrogens

Hot flush frequency (number/day) · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 711 participants
Low

Transdermal beta‐estradiol patch vs conjugated equine estrogens

Adverse events Beta‐estradiol patch 0.05 or 0.1 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 711 participants
Very low

Oral beta‐estradiol vs conjugated equine estrogens

Frequency of hot flushes Oral beta‐estradiol 1.0 and 2.0 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Very low

Oral beta‐estradiol vs conjugated equine estrogens

Adverse events Oral beta‐estradiol 1.0 or 2.0 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Very low

Transdermal beta‐estradiol patch vs placebo

Intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day · women with hot flushes

Transdermal beta‐estradiol patch showed no clear difference in intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day compared with placebo (low certainty).

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 393 participants
Low

Transdermal beta‐estradiol patch vs placebo

Adverse effects Beta‐estradiol patch dose 0.10 mg/day · women with hot flushes

Transdermal beta‐estradiol patch may leads to higher adverse effects Beta‐estradiol patch dose 0.10 mg/day compared with placebo (low certainty).

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
OR 2.14 [1.29, 3.54]
9 studies · 1822 participants
Low

Transdermal beta‐estradiol gel vs placebo

Hot flush frequency (number/day) · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 930 participants
Low

Transdermal beta‐estradiol gel vs placebo

Adverse effects Beta‐estradiol gel dose 1.5 mg/day · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1086 participants
Moderate

Oral beta‐estradiol vs placebo

Hot flush frequency (number/day) · women with hot flushes

Oral beta‐estradiol showed no clear difference in frequency of hot flushes Oral beta‐estradiol 0.5‐1.0 mg/day compared with placebo (low certainty).

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 356 participants
Low

Oral beta‐estradiol vs placebo

Adverse effects Oral beta‐estradiol 0.5‐2.0 mg/day · women with hot flushes

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 433 participants
Low

Topical beta‐estradiol emulsion vs placebo

Rate of vasomotor symptoms ‐ · women with vasomotor symptoms

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Low

Topical beta‐estradiol emulsion vs placebo

Adverse effects Micellar nanoparticle beta‐estradiol 8.6 mg/day · women with vasomotor symptoms

Topical beta‐estradiol emulsion showed no clear difference in adverse effects Micellar nanoparticle beta‐estradiol 8.6 mg/day compared with placebo (low certainty).

1 finding from 1 review

Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
OR 1.46 [0.8, 2.66]
1 study · 200 participants
Low

Intervention not reported

Total duration of mechanical ventilation (days) · Neonates with PPHN

The intervention showed no clear difference in total duration of mechanical ventilation (days) (low certainty).

1 finding from 1 review

Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants 2016 · Cochrane Headline outcomes only
no estimate extracted
37 participants
Low

Intervention not reported

Duration of iNO therapy (days) · Neonates with PPHN

1 finding from 1 review

Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants 2016 · Cochrane Headline outcomes only
no estimate extracted
21 participants
Low

Intervention not reported

Total duration of mechanical ventilation (days) · Neonates with PPHN

1 finding from 1 review

Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants 2016 · Cochrane Headline outcomes only
no estimate extracted
21 participants
Low

Pyridoxine vs placebo

Length of hospital stay · Pregnant women with hyperemesis gravidarum

1 finding from 1 review

Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 92 participants
Moderate

Metoclopramide vs ondansetron

Severity, reduction or cessation in nausea/vomiting 2.Days of hospital admission 3. Pregnancy complications 4. Adverse fetal/neonatal outcomes · Pregnant women with hyperemesis gravidarum

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metoclopramide vs promethazine

Severity, reduction or cessation in nausea/vomiting 2. Number of episodes of emesis 3. Days of hospital admission 4. Pregnancy complications 5. Adverse fetal/neonatal outcomes · Pregnant women with hyperemesis gravidarum

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ondansetron vs promethazine

Length of hospital stay · Pregnant women with hyperemesis gravidarum

It is very uncertain whether ondansetron changes days of hospital admission compared with promethazine (very low certainty).

1 finding from 1 review

Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Corticosteroids vs promethazine

Severe nausea 17th day · Pregnant women with hyperemesis gravidarum

It is very uncertain whether corticosteroids changes severe nausea 17th day compared with promethazine (very low certainty).

1 finding from 1 review

Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
RR 0.81 [0.58, 1.15]
1 study · 78 participants
Very low